My interests are in mechanisms of drug resistance, particularly in cancers retaining the p53 tumor suppressor in its wild-type state. Normally, the presence of wild-type p53 in cancers provides an apoptotic stimulus and imparts high tumor cell sensitivity to therapeutic agents. In resistant cancers, however, wild-type p53 fails to activate cell cycle checkpoint response and induce the apoptotic stimulus. The goal in my laboratory is to undertake hypothesis-driven studies to define pathways responsible for this loss of p53 function and rationally investigate designer drugs to reactivate the tumor suppressor and provide a basis for translational opportunities. Such an approach is essential for improving response rates in the clinic. In our laboratory, we use a variety of analytical tools to assess pharmacological (e.g., drug concentration at the cellular level and target sites), biochemical (e.g., checkpoint kinase activity and proteomic analysis), and molecular (e.g., target activation, microarrays and siRNA) drivers of cytotoxic drug response and their modulation in sensitive and resistant tumor models. There are ample opportunities to network with other labs with mutual interests.
Publications/Creative Works
Click here to search for this faculty member's publications on PubMed.
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.